Toggle menu

3CPO Trial

Start date:
Historic
End date:
April 2007
Co-ordinated by:
NHS Lothian

A randomised controlled trial of continuous positive airway pressure (CPAP) vs non invasive ventilation (NIV) vs standard therapy for acute pulmonary odema (ACPO)

 

Aim

To determine whether non invasive ventilation reduces mortality and whether there are important differences in outcome associated with the method of treatment (CPAP or NIPPV).

Trial Design

Multi centre randomised controlled trial of continuous positive airway pressure (CPAP) vs non invasive ventilation (NIV) vs standard therapy for acute pulmonary odema (ACPO)

List of Publications – references

A Gray, S Goodacre, D Newby, M Masson, F Sampson and J Nicholl on behalf of the 3CPO triallists. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema. New England Journal of Medicine. (2008);359:24-33.

A Gray, S Goodacre, D Newby, M Masson, F Sampson and J Nicholl on behalf of the 3CPO triallists. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema. Health Technology Assessment. (2009);13(33).

A Gray, S Goodacre, J Nicholl, M Masson, F Sampson, Mark Elliott, S Crane and DE Newby, on behalf of the 3CPO triallists. A development of a simple risk score to predict early outcome in severe acute cardiogenic pulmonary edema with acidosis: The 3CPO score. Circulation – Heart Failure. (2010);3:111-117.

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.